BK polyoma virus (BKPyV) is a double stranded DNA polyomavirus colonizing the urinary tract in early life [1] . BKPyV seroprevalence of is about 90%, however clinical manifestations is only seen in immuno-suppressed individuals (e.g., solid-organ transplant recipients) [2] . Virus reactivation may lead to hemorrhagic cystitis (HC) in hematopoietic stem cell transplantation (HSCT) causing significant morbidity [3] . BKPyV cystitis typically occurs early upon HSCT in approximately 13% (5-25%) of patients [3, 4] . Symptoms vary widely from mild dysuria, painless hematuria to painful hematuria or even severe HC with intravesical clotting and urethral obstruction and potential secondary renal failure [3, 5] .
No standard treatment of BKPyV cystitis exists. Reducing immunosuppression is recommended in the absence of co-existing graft versus host disease (GvHD). There's no licensed antiviral medication for BKPyV, but many case series evaluated intravenous (i.v.) cidofovir in BKPyV infection after HSCT, with response ranging from 47 to 88% [6, 7] . However, i.v. cidofovir induces substantial renal toxicity [7] , which is a major issue in HSCT setting. As an alternative, intravesical may substitute i.v. application by limiting local BKPyV replication while minimizing systemic side effects. In line with this idea, case reports and small case series reported efficacy of this approach [8, 9] .
Here we report a systematic retrospective single centre analysis of BKPyV cystitis cases occurring between 2012 and 2016 at our HSCT program. We focused on safety and efficacy of intravesical cidofovir application as 1st line therapy of symptomatic BKPyV cystitis. This is at least to our knowledge the largest analysis of this procedure reported so far, which supports the concept of intravesical cidofovir therapy as standard 1st line therapy in symptomatic BKPyV cystitis after HSCT. Diagnosis of BKPyV cystitis requires dysuria or HC, absence of bacterial/fungal urinary tract infection and BKPyV detection in the urine. Severity of HC was graded according to Bedi et al. [5] . Intravesical treatment consisted of 5 mg/kg cidofovir diluted in 90 ml sterile water installed for 60 min via transurethral catheter. The procedure was repeated weekly until symptoms improved. In case no clinical improvement could be achieved upon three intravesical applications, i.v. cidofovir was given.
From 166 patients, 22 (13%) patients developed symptomatic BKPyV cystitis (for patients details see Table 1 ). More than half of these 22 cases suffered from combined dysuria and hematuria (59%), whereas nine patients (41%) had only dysuria without hematuria (Table 2) . Sixty-four percent had active acute GvHD II°-IV°at BKPyV cystitis onset and 77% received concurrent steroid-medication (at least 5 mg prednisolone/day). Median time to symptom occurrence was 36 days after HSCT. Overall survival of patients with BKPyV cystitis was 59% at month 12 and 50% month 24.
Five out of 22 patients didn't require treatment as symptoms were self-limiting. The other 17 patients required specific treatment. In this patient group, time to BKPyV cystitis onset was median 35 days. In treated patients 29% (5/17) had only dysuria whereas 71% (12/17) had combined dysuria/hematuria (Table 2) . Most (77%) of the BKPyV cystitis patients had aGvHD II-IV°during the first 100 days. Cytomegalovirus (CMV) reactivation was detected in ten of the BKPyV cystitis patients.
The first patient with BKPyV cystitis was treated with i.v. cidofovir twice and symptoms resolved, but renal toxicity CTCAE I°occured. Therefore, we switched the regimen after this patient to 1st line intravesical cidofovir and the following 16 patients were treated with intravesical cidofovir 1st line. Using this approach ten patients (63%) achieved a complete remission after a median of two intravesical procedures. Two patients showed symptom improvement after a median of 2.5 intravesical therapies and finally, all these 12 patients didn't require further BKPyV-specific therapy. Thus, the overall response rate was 75%. One patient didn't tolerate intravesical cidofovir application because of bladder spasms and was switched to i.v. application. Three patients (19%) had insufficient symptom control and were therefore switched to i.v. therapy. From these four patients two responded (one complete and one partial response). The other two patients did not profit from i.v. cidofovir treatment and died from sepsis on day +81 and day +142. In the therapy group median BKPyV concentration at symptom onset was 2log10 higher than in patients with spontaneous symptom relief reaching 5 × 10 9 geq/ml. Clinical improvement of cystitis was accompanied by an approximately 2log reduction of BKPyV load in the urine (median BKPyV load in the urine to 7 × 10 7 geq/ml post therapy). Pain and spasms were exclusive for intravesical treatment and seen in 50% of patients (25% CTCAE I°, 25% CTCAE II°). No systemic toxicities were observed by local administration, particularly no renal toxicity. In contrast, 40% of patients with i.v. treatment developed renal toxicity (one acute kidney injuries, CTCAE I°and CTCAE II°; p = 0.048 versus local therapy). The incidence of BKPyV cystitis reported in our study is comparable to others [4] , and underscores that it represents a frequent complication after HSCT. The clinical onset of BKPyV cystitis after a median of 36 days is also comparable with results from a previously published retrospective EBMT analysis [8] . Several risk factors were described for BKPyV cystitis, including the stem cell source [3] , antithymocyte globulin (ATG) use and mismatch transplantations [10] . In our cohort all patients received peripheral blood stem cells and many patients received steroids due to co-existing aGvHD. Moreover, 53% of patients requiring BKPyV-specific therapy received stem cells from a mismatched donor and 66% received ATG as GvHD prophylaxis. Additional co-reactivations/infections with other viruses reflects the immunosuppressive status as known risk factor for BKPyV cystitis [11] . Accordingly, in our cohort 59% of the BKPyV cases also had CMV reactivation within the 1st 100 days, which is in line with findings by others showing that 59% of patients with CMV viremia experienced BKPyV cystitis whereas only 22% of patients without CMV reactivation developed BKPyV cystitis [12] . aGvHD is a known risk factor for viral reactions [13] , which was also verified here, as 64% of all BKPyV cases suffered from aGvHD II-IV°and 73% received steroid-medication (≥5 mg/d) at the time of BKPyV cystitis. The most recent ECIL recommendations are focusing on treatment of BKPyV hemorraghic cystitis (HC of at least II°) (https://www.ebmt.org/Contents/Resources/Library/ ECIL/Documents/2015%20ECIL6/ECIL6-BK-virus-08-12-2015-Cesaro-S-et-al%20final.pdf). In our cohort not all BKPyV cystitis HC < II°required treatment, as observed in three patients who had only dysuria and HC ≤ II°and whose BKPyV cystitis was self-limiting, most likely as a result of endogenous viral clearance by sufficient T cell-mediated viral clearance. However, we observed a relevant subgroup (n = 7), who had HC < II°requiring therapy because of sustained severe bladder pain and dysuria. This is in line with others showing a treatment rate of 30% in patients with HC < II° [7] . Thus treatment should be guided not only by HC grading but also by clinical symptoms.
The main goal of this project was safety and efficacy analysis of topical antiviral therapy in BKPyV cystitis. We here report the largest series of topical cidofovir therapy with an overall response rate of 75%. This is in agreement with smaller series including the so far largest cohort (n = 6) with a 100% response rate [9] . We here provide a stepwise escalation approach, which recommends switch to the potentially more toxic i.v. treatment in case topical therapy fails. Previous reports demonstrated clinical improvement after a median of four cycles [9] , which suggests that after at the latest four topical application without clear clinical improvement therapy should be switched. Response rate for i.v. 2nd line therapy in our cohort was 50%, but the group is too small and heterogenous to draw definitive conclusions. The response rates of 1st line i.v. cidofovir range from 47-100% [6, 10, 14] . Low-dose i.v. cidofovir therapy (1 mg/kg/week) induced remission in 85% [7] . If patients with more severe cystitis are included, the response rates were lower [3] . This may explain the relatively low response rate seen in our 2nd line cohort, in which one of the two i.v. non-responders had HC IV°and concomitant adenovirus viremia, and the second non-responder had co-existing EBV reactivation. Comparing toxicities in the two different application routes, a clearly higher renal toxicity was observed in the i.v. group (40% CTC I-II°), whereas none of the topical therapy developed renal complications. This is in accordance with others describing renal failure rates of 26-30% after i.v. cidofovir [7, 8] . This is at least in part a result of co-medication with other potential nephrotoxic drugs [14] . In contrast, intravesical cidofovir application induces only very mild side local effects [9] . The fact that BKPyV cystitis appears early after HSCT when comedication with additional potentially nephrotoxic medications (e.g., calcineurin-inhibitors, antiviral prophylaxis) is required, further supports the non-nephrotoxic topical therapy with cidofovir. However, other concurrent viral infections also often exist (such as CMV or Adenvirus infection), which requires i.v. therapy.
In summary, intravesical treatment of symptomatic BKPyV cystitis with cidofovir (5 mg/kg) is safe and effective, with an overall response rate of 75% and without relevant systemic toxicities. For patients with insufficient symptom control, i.v. cidofovir therapy is still an option, which however may induce significant renal toxicity. Based on this data, intravesical cidofovir as 1st line therapy of symptomatic BKPyV cystitis after HSCT may be an affective option. However, the retrospective single-center design of this study limits its power to draw definite conclusions and prospective controlled trials are warranted to test topical versus systemic treatment of BKPyV cystitis.
Compliance with ethical standards
